China · Delayed Price · Currency is CNY Hualan Biological Vaccine Statistics
Total Valuation
SHE:301207 has a market cap or net worth of CNY 11.97 billion. The enterprise value is 8.90 billion.
| Market Cap | 11.97B |
| Enterprise Value | 8.90B |
Important Dates
The next confirmed earnings date is Wednesday, October 28, 2026.
| Earnings Date | Oct 28, 2026 |
| Ex-Dividend Date | Jun 15, 2026 |
Share Statistics
SHE:301207 has 595.00 million shares outstanding. The number of shares has increased by 0.11% in one year.
| Current Share Class | 595.00M |
| Shares Outstanding | 595.00M |
| Shares Change (YoY) | +0.11% |
| Shares Change (QoQ) | +0.16% |
| Owned by Insiders (%) | 0.26% |
| Owned by Institutions (%) | 2.35% |
| Float | 97.10M |
Valuation Ratios
The trailing PE ratio is 60.33 and the forward PE ratio is 55.86.
| PE Ratio | 60.33 |
| Forward PE | 55.86 |
| PS Ratio | 10.08 |
| PB Ratio | 2.27 |
| P/TBV Ratio | 2.28 |
| P/FCF Ratio | 29.52 |
| P/OCF Ratio | 28.67 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 33.84, with an EV/FCF ratio of 21.97.
| EV / Earnings | 44.85 |
| EV / Sales | 7.50 |
| EV / EBITDA | 33.84 |
| EV / EBIT | 73.13 |
| EV / FCF | 21.97 |
Financial Position
The company has a current ratio of 4.42
| Current Ratio | 4.42 |
| Quick Ratio | 3.99 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 3.55% and return on invested capital (ROIC) is 4.39%.
| Return on Equity (ROE) | 3.55% |
| Return on Assets (ROA) | 1.15% |
| Return on Invested Capital (ROIC) | 4.39% |
| Return on Capital Employed (ROCE) | 2.30% |
| Weighted Average Cost of Capital (WACC) | 7.54% |
| Revenue Per Employee | 1.68M |
| Profits Per Employee | 280,460 |
| Employee Count | 708 |
| Asset Turnover | 0.18 |
| Inventory Turnover | 0.89 |
Taxes
In the past 12 months, SHE:301207 has paid 13.47 million in taxes.
| Income Tax | 13.47M |
| Effective Tax Rate | 6.35% |
Stock Price Statistics
The stock price has increased by +16.38% in the last 52 weeks. The beta is 0.60, so SHE:301207's price volatility has been lower than the market average.
| Beta (5Y) | 0.60 |
| 52-Week Price Change | +16.38% |
| 50-Day Moving Average | 17.96 |
| 200-Day Moving Average | 18.93 |
| Relative Strength Index (RSI) | 63.18 |
| Average Volume (20 Days) | 8,873,642 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, SHE:301207 had revenue of CNY 1.19 billion and earned 198.57 million in profits. Earnings per share was 0.33.
| Revenue | 1.19B |
| Gross Profit | 853.92M |
| Operating Income | 121.77M |
| Pretax Income | 212.04M |
| Net Income | 198.57M |
| EBITDA | 263.13M |
| EBIT | 121.77M |
| Earnings Per Share (EPS) | 0.33 |
Balance Sheet
The company has 3.06 billion in cash and no debt, with a net cash position of 3.06 billion or 5.14 per share.
| Cash & Cash Equivalents | 3.06B |
| Total Debt | n/a |
| Net Cash | 3.06B |
| Net Cash Per Share | 5.14 |
| Equity (Book Value) | 5.26B |
| Book Value Per Share | 8.85 |
| Working Capital | 3.40B |
Cash Flow
In the last 12 months, operating cash flow was 417.36 million and capital expenditures -12.08 million, giving a free cash flow of 405.28 million.
| Operating Cash Flow | 417.36M |
| Capital Expenditures | -12.08M |
| Depreciation & Amortization | 141.37M |
| Net Borrowing | n/a |
| Free Cash Flow | 405.28M |
| FCF Per Share | 0.68 |
Margins
Gross margin is 71.94%, with operating and profit margins of 10.26% and 16.73%.
| Gross Margin | 71.94% |
| Operating Margin | 10.26% |
| Pretax Margin | 17.86% |
| Profit Margin | 16.73% |
| EBITDA Margin | 22.17% |
| EBIT Margin | 10.26% |
| FCF Margin | 34.14% |
Dividends & Yields
This stock pays an annual dividend of 1.60, which amounts to a dividend yield of 7.96%.
| Dividend Per Share | 1.60 |
| Dividend Yield | 7.96% |
| Dividend Growth (YoY) | 600.00% |
| Years of Dividend Growth | 3 |
| Payout Ratio | 443.98% |
| FCF Payout Ratio | 205.54% |
| Buyback Yield | -0.11% |
| Shareholder Yield | 7.85% |
| Earnings Yield | 1.66% |
| FCF Yield | 3.39% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for SHE:301207 is 25.57, which is 27.15% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 25.57 |
| Price Target Difference | 27.15% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | 14.18% |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
The last stock split was on June 7, 2023. It was a forward split with a ratio of 1.5.
| Last Split Date | Jun 7, 2023 |
| Split Type | Forward |
| Split Ratio | 1.5 |
Scores
SHE:301207 has an Altman Z-Score of 8.17 and a Piotroski F-Score of 5.
| Altman Z-Score | 8.17 |
| Piotroski F-Score | 5 |